Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 12/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4252171 | 1.00 | TACR1 (0.51) | TACR1PDE4BCYP3A4CYP2D6GPR119 | |
| SCHEMBL4252177 | 1.00 | TACR1 (0.51) | TACR1PDE4BCYP3A4CYP2D6GPR119 | |
| SCHEMBL4258314 | 0.91 | PDE4B (0.48) | TACR1PDE4BGPR119HDAC1HDAC2 | |
| SCHEMBL4258309 | 0.91 | PDE4B (0.48) | TACR1PDE4BGPR119HDAC1HDAC2 | |
| SCHEMBL14028095 | 0.91 | PDE4B (0.48) | TACR1PDE4BGPR119HDAC1HDAC2 | |
| SCHEMBL4258319 | 0.91 | PDE4B (0.48) | TACR1PDE4BGPR119HDAC1HDAC2 | |
| SCHEMBL18971977 | 0.90 | TACR1 (0.47) | TACR1CYP3A4CYP2D6GPR119BRD3 | |
| SCHEMBL5005980 | 0.90 | TACR1 (0.48) | TACR1CYP3A4CYP2D6GPR119HDAC1 | |
| SCHEMBL4153158 | 0.90 | TACR1 (0.48) | TACR1CYP3A4CYP2D6GPR119HDAC1 | |
| SCHEMBL4408595 | 0.90 | TACR1 (0.48) | TACR1CYP3A4CYP2D6GPR119HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | TANABE SEIYAKU CO., LTD. (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | TANABE SEIYAKU CO., LTD. (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | TANABE SEIYAKU CO., LTD. (JP) | 2009-01-01 | — | — | US | disclosed |
| US-20070244158-A1 | Piperdine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070244158-A1 | Piperdine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070244158-A1 | Piperdine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-10-18 | — | — | US | disclosed |
| EP-1789389-A1 | PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006030984-A1 | PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244158-A1 | Piperdine Compound and Process for Preparing the Same | AVPR1B, PRLHR, HRH4 | TACR1 12/4885PDE4B 1273/4885CYP3A4 901/4885 |
| US-20090005355-A1 | Piperidine Compound and Process for Preparing the Same | AVPR1B, HRH4, PRLHR | TACR1 6/4885PDE4B 1656/4885CYP3A4 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.